NAD+ (Nicotinamide Adenine Dinucleotide) is a naturally occurring coenzyme found in virtually every living cell. It is an essential molecule involved in cellular energy production, mitochondrial function, DNA repair, cellular signaling, and healthy aging. NAD+ exists in two primary forms: the oxidized form (NAD+) and the reduced form (NADH), which continuously cycle during cellular metabolism.
NAD+ serves as a critical cofactor in hundreds of enzymatic reactions, particularly those involved in the production of adenosine triphosphate (ATP), the primary energy currency of the cell. In addition to its metabolic role, NAD+ is required for the activity of enzymes such as sirtuins (SIRT1–SIRT7), poly(ADP-ribose) polymerases (PARPs), and CD38, which are involved in DNA repair, inflammation, mitochondrial health, circadian rhythm regulation, and cellular aging.
Because NAD+ levels naturally decline with age and in certain chronic diseases, there has been increasing scientific interest in therapies designed to restore intracellular NAD+ concentrations. However, NAD+ itself is not FDA-approved as a prescription medication for anti-aging, chronic fatigue, cognitive enhancement, athletic performance, or longevity. While intravenous NAD+ is offered by some wellness clinics, these uses remain investigational.
NAD+ is a central regulator of cellular metabolism and mitochondrial function.
Research suggests NAD+ may:
Unlike most peptide therapies, NAD+ is not a hormone or receptor agonist. Instead, it functions as a universal metabolic coenzyme required for normal cellular function.
Research suggests maintaining healthy NAD+ levels may support numerous physiologic processes.
Potential benefits may include:
Although supplementation strategies designed to increase NAD+ have generated significant interest, direct evidence that intravenous or injectable NAD+ improves longevity, athletic performance, or chronic disease outcomes remains limited.
Published clinical studies suggest NAD+ administration is generally well tolerated, although adverse effects can occur, particularly with rapid intravenous infusion.
Potential side effects include:
Most infusion-related side effects improve by slowing the infusion rate. Long-term safety of repeated high-dose intravenous NAD+ administration has not been well established.
Formal contraindications have not been established because NAD+ is not FDA-approved as a prescription drug.
Based on current knowledge, caution is advised in individuals with:
Patients with significant chronic medical conditions should consult a qualified healthcare provider before receiving intravenous or injectable NAD+.
NAD+ is NOT FDA-approved as a prescription medication for any medical indication in the United States.
It is not FDA-approved for:
While numerous dietary supplements are marketed to increase NAD+ through precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), these products should not be interpreted as FDA-approved therapies.
Human Studies
Human research involving NAD+ has expanded rapidly over the past decade.
Clinical investigations have evaluated NAD+ or NAD+-boosting strategies for:
Most clinical trials have focused on increasing intracellular NAD+ using precursors such as nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN), rather than administering NAD+ directly. These studies consistently demonstrate increases in blood NAD+ concentrations; however, improvements in clinical outcomes have been variable, and additional large randomized controlled trials are needed.
Evidence supporting intravenous NAD+ therapy for wellness, anti-aging, addiction, or athletic performance remains limited.
Animal & Preclinical Studies
Animal studies have demonstrated that increasing NAD+ availability may:
These findings have established NAD+ as one of the most important molecules in aging and mitochondrial biology, although translation to humans remains an area of active investigation.
Human Studies
Safety and Metabolism of Long-Term Administration of Nicotinamide Riboside in Healthy Adults https://pubmed.ncbi.nlm.nih.gov/31278280/
Animal & Preclinical Studies
Review Articles
Sobriety and Satiety: Is NAD+ the Answer?
<strong>https://pmc.ncbi.nlm.nih.gov/articles/PMC7278809/</strong>
The information provided on this page is intended for educational and informational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease and should not be considered medical advice.
This content was generated with the assistance of artificial intelligence (AI) and should be reviewed by a qualified medical professional before publication or clinical use. AI-generated medical content may contain errors, omissions, outdated information, or incomplete interpretations of the available scientific literature.
NAD+ is not FDA-approved as a prescription medication for anti-aging, cognitive enhancement, chronic fatigue, longevity, or other wellness-related indications. Current evidence supports its critical role in cellular metabolism and mitochondrial function, but additional high-quality clinical studies are needed to establish the safety and effectiveness of intravenous or injectable NAD+ therapies. Individual results vary, and no specific outcome or benefit can be guaranteed. Patients should consult a qualified healthcare provider before beginning or changing any medical treatment.
R2 Medical Clinic uses medications sourced from compounding pharmacies. Compounded medications are not approved by the U.S. Food and Drug Administration (FDA). Unlike FDA-approved medications, compounded drugs have not undergone FDA review for safety, effectiveness, or efficacy through the FDA drug approval process. While 503B outsourcing facilities are registered with and inspected by the FDA and must comply with Current Good Manufacturing Practice (CGMP) requirements, the compounded medications they produce are not individually approved by the FDA. Similarly, compounded medications prepared by 503A pharmacies are not FDA-approved and are primarily regulated by state boards of pharmacy, with FDA oversight under applicable federal law.